Unique mechanistic insights into the beneficial effects of soluble epoxide hydrolase inhibitors in the prevention of cardiac fibrosis

Padmini Sirish, Ning Li, Jun Yan Liu, Kin Sing Stephen Lee, Sung Hee Hwang, Hong Qiu, Cuifen Zhao, Siu Mei Ma, Javier E Lopez, Bruce D. Hammock, Nipavan Chiamvimonvat

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Tissue fibrosis represents one of the largest groups of diseases for which there are very few effective therapies. In the heart, myocardial infarction (MI) resulting in the loss of cardiac myocytes can culminate in adverse cardiac remodeling leading to eventual heart failure. Adverse cardiac remodeling includes myocyte hypertrophy, fibrosis, and electrical remodeling. Wehave previously demonstrated the beneficial effects of several potent soluble epoxide hydrolase inhibitors (sEHIs) in different models of cardiac hypertrophy and failure. Here,we directly determine themolecular mechanisms underlying the beneficial effects of sEHIs in cardiac remodeling post-MI. Treatment with a potent sEHI, 1-trifluoromethoxyphenyl-3-(1-propionylpiperidine- 4-yl)urea (TPPU), whichwas started 1 wk post-MI in a murine model, results in a significant improvement in cardiac function. Importantly, treatment with TPPU results in a decrease in cardiac fibrosis as quantified using histological and immunostaining techniques. Moreover, single-cell-based assays demonstrate that treatment with TPPU results in a significant decrease not only in the percentages but also the proliferative capacity of different populations of cardiac fibroblasts as well as a reduction in the migration of fibroblasts into the heart from the bone marrow. Our study provides evidence for a possible unique therapeutic strategy to reduce cardiac fibrosis and improve cardiac function post-MI.

Original languageEnglish (US)
Pages (from-to)5618-5623
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume110
Issue number14
DOIs
StatePublished - Apr 2 2013

Fingerprint

Epoxide Hydrolases
Fibrosis
Myocardial Infarction
Heart Failure
Fibroblasts
Atrial Remodeling
Histological Techniques
Cardiomegaly
Cardiac Myocytes
Muscle Cells
Hypertrophy
Bone Marrow
Therapeutics
Population

Keywords

  • Cluster of Differentiation 91
  • Dihydroxyeicosatrienoic acids
  • Epoxyeicosatrienoic acids
  • Fibroblast specific protein 1
  • Thymocyte differentiation antigen

ASJC Scopus subject areas

  • General

Cite this

Unique mechanistic insights into the beneficial effects of soluble epoxide hydrolase inhibitors in the prevention of cardiac fibrosis. / Sirish, Padmini; Li, Ning; Liu, Jun Yan; Lee, Kin Sing Stephen; Hwang, Sung Hee; Qiu, Hong; Zhao, Cuifen; Ma, Siu Mei; Lopez, Javier E; Hammock, Bruce D.; Chiamvimonvat, Nipavan.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 110, No. 14, 02.04.2013, p. 5618-5623.

Research output: Contribution to journalArticle

Sirish, Padmini ; Li, Ning ; Liu, Jun Yan ; Lee, Kin Sing Stephen ; Hwang, Sung Hee ; Qiu, Hong ; Zhao, Cuifen ; Ma, Siu Mei ; Lopez, Javier E ; Hammock, Bruce D. ; Chiamvimonvat, Nipavan. / Unique mechanistic insights into the beneficial effects of soluble epoxide hydrolase inhibitors in the prevention of cardiac fibrosis. In: Proceedings of the National Academy of Sciences of the United States of America. 2013 ; Vol. 110, No. 14. pp. 5618-5623.
@article{1135cbd6846144c2b5b34ad713f996f1,
title = "Unique mechanistic insights into the beneficial effects of soluble epoxide hydrolase inhibitors in the prevention of cardiac fibrosis",
abstract = "Tissue fibrosis represents one of the largest groups of diseases for which there are very few effective therapies. In the heart, myocardial infarction (MI) resulting in the loss of cardiac myocytes can culminate in adverse cardiac remodeling leading to eventual heart failure. Adverse cardiac remodeling includes myocyte hypertrophy, fibrosis, and electrical remodeling. Wehave previously demonstrated the beneficial effects of several potent soluble epoxide hydrolase inhibitors (sEHIs) in different models of cardiac hypertrophy and failure. Here,we directly determine themolecular mechanisms underlying the beneficial effects of sEHIs in cardiac remodeling post-MI. Treatment with a potent sEHI, 1-trifluoromethoxyphenyl-3-(1-propionylpiperidine- 4-yl)urea (TPPU), whichwas started 1 wk post-MI in a murine model, results in a significant improvement in cardiac function. Importantly, treatment with TPPU results in a decrease in cardiac fibrosis as quantified using histological and immunostaining techniques. Moreover, single-cell-based assays demonstrate that treatment with TPPU results in a significant decrease not only in the percentages but also the proliferative capacity of different populations of cardiac fibroblasts as well as a reduction in the migration of fibroblasts into the heart from the bone marrow. Our study provides evidence for a possible unique therapeutic strategy to reduce cardiac fibrosis and improve cardiac function post-MI.",
keywords = "Cluster of Differentiation 91, Dihydroxyeicosatrienoic acids, Epoxyeicosatrienoic acids, Fibroblast specific protein 1, Thymocyte differentiation antigen",
author = "Padmini Sirish and Ning Li and Liu, {Jun Yan} and Lee, {Kin Sing Stephen} and Hwang, {Sung Hee} and Hong Qiu and Cuifen Zhao and Ma, {Siu Mei} and Lopez, {Javier E} and Hammock, {Bruce D.} and Nipavan Chiamvimonvat",
year = "2013",
month = "4",
day = "2",
doi = "10.1073/pnas.1221972110",
language = "English (US)",
volume = "110",
pages = "5618--5623",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "14",

}

TY - JOUR

T1 - Unique mechanistic insights into the beneficial effects of soluble epoxide hydrolase inhibitors in the prevention of cardiac fibrosis

AU - Sirish, Padmini

AU - Li, Ning

AU - Liu, Jun Yan

AU - Lee, Kin Sing Stephen

AU - Hwang, Sung Hee

AU - Qiu, Hong

AU - Zhao, Cuifen

AU - Ma, Siu Mei

AU - Lopez, Javier E

AU - Hammock, Bruce D.

AU - Chiamvimonvat, Nipavan

PY - 2013/4/2

Y1 - 2013/4/2

N2 - Tissue fibrosis represents one of the largest groups of diseases for which there are very few effective therapies. In the heart, myocardial infarction (MI) resulting in the loss of cardiac myocytes can culminate in adverse cardiac remodeling leading to eventual heart failure. Adverse cardiac remodeling includes myocyte hypertrophy, fibrosis, and electrical remodeling. Wehave previously demonstrated the beneficial effects of several potent soluble epoxide hydrolase inhibitors (sEHIs) in different models of cardiac hypertrophy and failure. Here,we directly determine themolecular mechanisms underlying the beneficial effects of sEHIs in cardiac remodeling post-MI. Treatment with a potent sEHI, 1-trifluoromethoxyphenyl-3-(1-propionylpiperidine- 4-yl)urea (TPPU), whichwas started 1 wk post-MI in a murine model, results in a significant improvement in cardiac function. Importantly, treatment with TPPU results in a decrease in cardiac fibrosis as quantified using histological and immunostaining techniques. Moreover, single-cell-based assays demonstrate that treatment with TPPU results in a significant decrease not only in the percentages but also the proliferative capacity of different populations of cardiac fibroblasts as well as a reduction in the migration of fibroblasts into the heart from the bone marrow. Our study provides evidence for a possible unique therapeutic strategy to reduce cardiac fibrosis and improve cardiac function post-MI.

AB - Tissue fibrosis represents one of the largest groups of diseases for which there are very few effective therapies. In the heart, myocardial infarction (MI) resulting in the loss of cardiac myocytes can culminate in adverse cardiac remodeling leading to eventual heart failure. Adverse cardiac remodeling includes myocyte hypertrophy, fibrosis, and electrical remodeling. Wehave previously demonstrated the beneficial effects of several potent soluble epoxide hydrolase inhibitors (sEHIs) in different models of cardiac hypertrophy and failure. Here,we directly determine themolecular mechanisms underlying the beneficial effects of sEHIs in cardiac remodeling post-MI. Treatment with a potent sEHI, 1-trifluoromethoxyphenyl-3-(1-propionylpiperidine- 4-yl)urea (TPPU), whichwas started 1 wk post-MI in a murine model, results in a significant improvement in cardiac function. Importantly, treatment with TPPU results in a decrease in cardiac fibrosis as quantified using histological and immunostaining techniques. Moreover, single-cell-based assays demonstrate that treatment with TPPU results in a significant decrease not only in the percentages but also the proliferative capacity of different populations of cardiac fibroblasts as well as a reduction in the migration of fibroblasts into the heart from the bone marrow. Our study provides evidence for a possible unique therapeutic strategy to reduce cardiac fibrosis and improve cardiac function post-MI.

KW - Cluster of Differentiation 91

KW - Dihydroxyeicosatrienoic acids

KW - Epoxyeicosatrienoic acids

KW - Fibroblast specific protein 1

KW - Thymocyte differentiation antigen

UR - http://www.scopus.com/inward/record.url?scp=84875859835&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875859835&partnerID=8YFLogxK

U2 - 10.1073/pnas.1221972110

DO - 10.1073/pnas.1221972110

M3 - Article

C2 - 23493561

AN - SCOPUS:84875859835

VL - 110

SP - 5618

EP - 5623

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 14

ER -